{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:18:06Z","timestamp":1790061486787,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","award":["MOH-StaR17Nov-001"],"award-info":[{"award-number":["MOH-StaR17Nov-001"]}],"id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","award":["SC35\/22-805100"],"award-info":[{"award-number":["SC35\/22-805100"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","award":["ACCL\/19-GAP064-R20H-H"],"award-info":[{"award-number":["ACCL\/19-GAP064-R20H-H"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"DOI":"10.1038\/s41423-023-01080-3","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T22:01:43Z","timestamp":1693864903000},"page":"1300-1312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0658-7629","authenticated-orcid":false,"given":"Qi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4169-7209","authenticated-orcid":false,"given":"Shou Kit","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Kun","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2340-0499","authenticated-orcid":false,"given":"Yanchun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zack","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-En","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Kunasegaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Tanoto","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0502-2527","authenticated-orcid":false,"given":"Nina","family":"Le Bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiew Yee","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Shan","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Renia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anantharaman","family":"Vathsala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-0485","authenticated-orcid":false,"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"1080_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrgastro.2012.67","volume":"9","author":"Q Pan","year":"2012","unstructured":"Pan Q, Tilanus HW, Metselaar HJ, Janssen HL, van der Laan LJ. Virus-drug interactions-molecular insight into immunosuppression and HCV. Nat Rev Gastroenterol Hepatol. 2012;9:355\u201362.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1080_CR2","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.trre.2020.100588","volume":"35","author":"MA Raja","year":"2021","unstructured":"Raja MA, Mendoza MA, Villavicencio A, Anjan S, Reynolds JM, Kittipibul V, et al. COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. Transpl Rev. 2021;35:100588.","journal-title":"Transpl Rev"},{"key":"1080_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/ajt.15941","volume":"20","author":"MR Pereira","year":"2020","unstructured":"Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020;20:1800\u20138.","journal-title":"Am J Transplant"},{"key":"1080_CR4","first-page":"101397","volume":"33","author":"F Simioli","year":"2021","unstructured":"Simioli F, Martino M, Annunziata A, Carannante N, Fiorentino G. Therapeutic approach for severe COVID-19 and immunocompromised patients. A case series. Respir Med Case Rep. 2021;33:101397.","journal-title":"Respir Med Case Rep"},{"key":"1080_CR5","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1097\/TP.0000000000004200","volume":"106","author":"RK Avery","year":"2022","unstructured":"Avery RK. Update on COVID-19 therapeutics for solid organ transplant recipients, including the omicron surge. Transplantation. 2022;106:1528\u201337.","journal-title":"Transplantation"},{"key":"1080_CR6","first-page":"1163","volume":"2","author":"A van Laarhoven","year":"2021","unstructured":"van Laarhoven A, Kurver L, Overheul GJ, Kooistra EJ, Abdo WF, van Crevel R, et al. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series. Medicne. 2021;2:1163\u201370.e2.","journal-title":"Medicne"},{"key":"1080_CR7","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1681\/ASN.2021040480","volume":"32","author":"D Bertrand","year":"2021","unstructured":"Bertrand D, Hamzaoui M, Lem\u00e9e V, Lamulle J, Hanoy M, Laurent C, et al. Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J Am Soc Nephrol. 2021;32:2147\u201352.","journal-title":"J Am Soc Nephrol"},{"key":"1080_CR8","doi-asserted-by":"publisher","first-page":"eabj1031","DOI":"10.1126\/sciimmunol.abj1031","volume":"6","author":"H Rincon-Arevalo","year":"2021","unstructured":"Rincon-Arevalo H, Choi M, Stefanski AL, Halleck F, Weber U, Szelinski F, et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021;6:eabj1031.","journal-title":"Sci Immunol"},{"key":"1080_CR9","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.immuni.2022.07.005","volume":"55","author":"Y Gao","year":"2022","unstructured":"Gao Y, Cai C, Wullimann D, Niessl J, Rivera-Ballesteros O, Chen P, et al. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity. 2022;55:1732\u201346.e5.","journal-title":"Immunity"},{"key":"1080_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","volume":"223","author":"JH Baang","year":"2021","unstructured":"Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223:23\u201327.","journal-title":"J Infect Dis"},{"key":"1080_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","volume":"222","author":"M Helleberg","year":"2020","unstructured":"Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech AM, Lane C, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222:1103\u20137.","journal-title":"J Infect Dis"},{"key":"1080_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jiac.2020.12.001","volume":"27","author":"Y Nakajima","year":"2021","unstructured":"Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2021;27:387\u20139.","journal-title":"J Infect Chemother"},{"key":"1080_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.12968\/bjon.2018.27.16.920","volume":"27","author":"R Cajanding","year":"2018","unstructured":"Cajanding R. Immunosuppression following organ transplantation. Part 1: mechanisms and immunosuppressive agents. Br J Nurs. 2018;27:920\u20137.","journal-title":"Br J Nurs"},{"key":"1080_CR14","doi-asserted-by":"publisher","first-page":"e168603","DOI":"10.1172\/JCI168603","volume":"133","author":"A Casadevall","year":"2023","unstructured":"Casadevall A, Focosi D. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. J Clin Investig. 2023;133:e168603.","journal-title":"J Clin Investig"},{"key":"1080_CR15","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","volume":"34","author":"AT Tan","year":"2021","unstructured":"Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021;34:108728.","journal-title":"Cell Rep"},{"key":"1080_CR16","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","volume":"116","author":"T Feuchtinger","year":"2010","unstructured":"Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116:4360\u20137.","journal-title":"Blood"},{"key":"1080_CR17","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","volume":"99","author":"P Comoli","year":"2002","unstructured":"Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592\u20138.","journal-title":"Blood"},{"key":"1080_CR18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/ajt.16927","volume":"22","author":"K Martits-Chalangari","year":"2022","unstructured":"Martits-Chalangari K, Spak CW, Askar M, Killian A, Fisher TL, Atillasoy E, et al. ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: case report. Am J Transplant. 2022;22:1261\u20135.","journal-title":"Am J Transplant"},{"key":"1080_CR19","doi-asserted-by":"crossref","unstructured":"Papadopoulou A, Karavalakis G, Papadopoulou E, Xochelli A, Bousiou Z, Vogiatzoglou A, et al. SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1\/2 trial. Nat Med. 2023;29:2019\u201329.","DOI":"10.1038\/s41591-023-02480-8"},{"key":"1080_CR20","doi-asserted-by":"crossref","unstructured":"Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, et al. Allogeneic off-the-shelf SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023;108:1840\u201350.","DOI":"10.3324\/haematol.2022.281946"},{"key":"1080_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.omtm.2022.02.012","volume":"25","author":"L Peter","year":"2022","unstructured":"Peter L, Wendering DJ, Schlickeiser S, Hoffmann H, Noster R, Wagner DL, et al. Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. Mol Ther Methods Clin Dev. 2022;25:52\u201373.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1080_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/hep.31662","volume":"74","author":"M Hafezi","year":"2021","unstructured":"Hafezi M, Lin M, Chia A, Chua A, Ho ZZ, Fam R, et al. Immunosuppressive drug-resistant armored T-cell receptor T cells for immune therapy of HCC in liver transplant patients. Hepatology. 2021;74:200\u201313.","journal-title":"Hepatology"},{"key":"1080_CR23","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1182\/blood-2009-07-230482","volume":"114","author":"B De Angelis","year":"2009","unstructured":"De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009;114:4784\u201391.","journal-title":"Blood"},{"key":"1080_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ymthe.2006.02.017","volume":"14","author":"P Yam","year":"2006","unstructured":"Yam P, Jensen M, Akkina R, Anderson J, Villacres MC, Wu J, et al. Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells. Mol Ther. 2006;14:236\u201344.","journal-title":"Mol Ther"},{"key":"1080_CR25","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1038\/mtna.2013.43","volume":"2","author":"S Koh","year":"2013","unstructured":"Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, et al. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids. 2013;2:e114.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1080_CR26","doi-asserted-by":"publisher","first-page":"e20191663","DOI":"10.1084\/jem.20191663","volume":"217","author":"A Bertoletti","year":"2020","unstructured":"Bertoletti A, Tan AT. Challenges of CAR- and TCR-T cell-based therapy for chronic infections. J Exp Med. 2020;217:e20191663.","journal-title":"J Exp Med"},{"key":"1080_CR27","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1172\/JCI93024","volume":"127","author":"J Kah","year":"2017","unstructured":"Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, L\u00fctgehetmann M, et al. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Investig. 2017;127:3177\u201388.","journal-title":"J Clin Investig"},{"key":"1080_CR28","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3389\/fimmu.2020.01626","volume":"11","author":"RB Polidoro","year":"2020","unstructured":"Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19. Front Immunol. 2020;11:1626.","journal-title":"Front Immunol"},{"key":"1080_CR29","doi-asserted-by":"publisher","first-page":"100793","DOI":"10.1016\/j.xcrm.2022.100793","volume":"3","author":"JME Lim","year":"2022","unstructured":"Lim JME, Hang SK, Hariharaputran S, Chia A, Tan N, Lee ES, et al. A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines. Cell Rep. Med. 2022;3:100793.","journal-title":"Cell Rep. Med"},{"key":"1080_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41590-021-01084-z","volume":"23","author":"Y Peng","year":"2022","unstructured":"Peng Y, Felce SL, Dong D, Penkava F, Mentzer AJ, Yao X, et al. An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat Immunol. 2022;23:50\u201361.","journal-title":"Nat Immunol"},{"key":"1080_CR31","doi-asserted-by":"publisher","first-page":"100193","DOI":"10.1016\/j.xcrm.2021.100193","volume":"2","author":"YS Goh","year":"2021","unstructured":"Goh YS, Chavatte JM, Lim Jieling A, Lee B, Hor PX, Amrun SN, et al. Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. Cell Rep. Med. 2021;2:100193.","journal-title":"Cell Rep. Med"},{"key":"1080_CR32","doi-asserted-by":"publisher","first-page":"1031852","DOI":"10.3389\/fimmu.2022.1031852","volume":"13","author":"YS Goh","year":"2022","unstructured":"Goh YS, Rouers A, Fong SW, Zhuo NZ, Hor PX, Loh CY, et al. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. Front Immunol. 2022;13:1031852.","journal-title":"Front Immunol"},{"key":"1080_CR33","doi-asserted-by":"publisher","first-page":"100671","DOI":"10.1016\/j.xpro.2021.100671","volume":"2","author":"YS Goh","year":"2021","unstructured":"Goh YS, Ng LFP, Renia L. A flow cytometry-based assay for serological detection of anti-spike antibodies in COVID-19 patients. STAR Protoc. 2021;2:100671.","journal-title":"STAR Protoc"},{"key":"1080_CR34","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.immuni.2023.02.017","volume":"56","author":"M Koutsakos","year":"2023","unstructured":"Koutsakos M, Reynaldi A, Lee WS, Nguyen J, Amarasena T, Taiaroa G, et al. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell response. Immunity. 2023;56:879\u2013892.e4.","journal-title":"Immunity"},{"key":"1080_CR35","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1111\/ajt.12475","volume":"13","author":"I Ricciardelli","year":"2013","unstructured":"Ricciardelli I, Brewin J, Lugthart G, Albon SJ, Pule M, Amrolia PJ. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. Am J Transplant. 2013;13:3244\u201352.","journal-title":"Am J Transplant"},{"key":"1080_CR36","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","volume":"156","author":"AT Tan","year":"2019","unstructured":"Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, et al. Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology. 2019;156:1862\u201376.e9.","journal-title":"Gastroenterology"},{"key":"1080_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","volume":"62","author":"W Qasim","year":"2015","unstructured":"Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol. 2015;62:486\u201391.","journal-title":"J Hepatol"},{"key":"1080_CR38","doi-asserted-by":"crossref","unstructured":"Tometten I, Landmann S, Kantauskaite M, Lamberti J, Hillebrandt J, M\u00fcller L, et al. Factors associated with vaccine-induced T cell immune responses against SARS-CoV-2 in kidney transplant recipients. J Infect Dis. 2022;227:641\u201350.","DOI":"10.1093\/infdis\/jiac449"},{"key":"1080_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32985-8","volume":"13","author":"MJ Scurr","year":"2022","unstructured":"Scurr MJ, Lippiatt G, Capitani L, Bentley K, Lauder SN, Smart K, et al. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nat Commun. 2022;13:5422.","journal-title":"Nat Commun"},{"key":"1080_CR40","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291\u20133.","journal-title":"N Engl J Med"},{"key":"1080_CR41","doi-asserted-by":"publisher","first-page":"e152379","DOI":"10.1172\/JCI152379","volume":"131","author":"AT Tan","year":"2021","unstructured":"Tan AT, Lim JM, Le Bert N, Kunasegaran K, Chia A, Qui MD, et al. Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. J Clin Investig. 2021;131:e152379.","journal-title":"J Clin Investig"},{"key":"1080_CR42","doi-asserted-by":"publisher","first-page":"eabq7647","DOI":"10.1126\/sciimmunol.abq7647","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Yu J, McMahan K, Jacob-Dolan C, He X, Giffin V, et al. CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques. Sci Immunol. 2022;7:eabq7647.","journal-title":"Sci Immunol"},{"key":"1080_CR43","doi-asserted-by":"publisher","first-page":"109432","DOI":"10.1016\/j.celrep.2021.109432","volume":"36","author":"R Basar","year":"2021","unstructured":"Basar R, Uprety N, Ensley E, Daher M, Klein K, Martinez F, et al. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep. 2021;36:109432.","journal-title":"Cell Rep"},{"key":"1080_CR44","doi-asserted-by":"publisher","first-page":"110345","DOI":"10.1016\/j.mehy.2020.110345","volume":"145","author":"CA Canas","year":"2020","unstructured":"Canas CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020;145:110345.","journal-title":"Med Hypotheses"},{"key":"1080_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41584-023-00964-y","volume":"19","author":"C Sharma","year":"2023","unstructured":"Sharma C, Bayry J. High risk of autoimmune diseases after COVID-19. Nat Rev Rheumatol. 2023;19:399\u2013400.","journal-title":"Nat Rev Rheumatol"},{"key":"1080_CR46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1182\/blood.2021013363","volume":"139","author":"D Quach","year":"2022","unstructured":"Quach D, Lulla P, Rooney CM. Banking on virus-specific T-cells (VSTS) to fulfill the need for \u201coff the shelf\u201d cell therapies. Blood. 2022;139:799\u2013802.","journal-title":"Blood"},{"key":"1080_CR47","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.immuni.2022.08.008","volume":"55","author":"A Bertoletti","year":"2022","unstructured":"Bertoletti A, Le Bert N, Tan AT. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity. 2022;55:1764\u201378.","journal-title":"Immunity"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-023-01080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-023-01080-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-023-01080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T20:02:32Z","timestamp":1698696152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-023-01080-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1038\/s41423-023-01080-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2745832\/v1","asserted-by":"object"}]},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"28 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB is a cofounder of and ATT consults for Lion TCR, a biotech company developing T-cell receptors for treatment of virus-related diseases and cancers. ZH and LEW are employees of Lion TCR Pte. Ltd. None of the other authors has any competing interests related to the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}